# Jingdong Chao

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jingdong-chao/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,221 |
| Field | Inflammatory Bowel Disease |
| h-index | 37 |
| i10-index | 67 |
| Last Known Institution | Regeneron (United States) |
| OpenAlex ID | https://openalex.org/A5104088201 |
| Works | 251 |

## Researcher papers

- [Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma](https://scholariq.org/papers/dupilumab-efficacy-and-safety-in-moderate-to-severe-uncontrolled-asthma/)
- [Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-glucocorticoid-dependent-severe-asthma/)
- [Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study](https://scholariq.org/papers/effects-of-adalimumab-therapy-on-incidence-of-hospitalization-and-surgery-in/)
- [Prevalence of Noninfectious Uveitis in the United States](https://scholariq.org/papers/prevalence-of-noninfectious-uveitis-in-the-united-states/)
- [Adalimumab Induces Deep Remission in Patients With Crohn's Disease](https://scholariq.org/papers/adalimumab-induces-deep-remission-in-patients-with-crohn-s-disease/)
- [Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial](https://scholariq.org/papers/effects-of-adalimumab-maintenance-therapy-on-health-related-quality-of-life-of/)
- [Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis](https://scholariq.org/papers/risk-of-ocular-complications-in-patients-with-noninfectious-intermediate-uveitis/)
- [The costs of Crohn's disease in the United States and other Western countries: a systematic review](https://scholariq.org/papers/the-costs-of-crohn-s-disease-in-the-united-states-and-other-western-countries-a/)
- [Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma](https://scholariq.org/papers/liberty-asthma-quest-phase-3-randomized-double-blind-placebo-controlled-parallel/)
- [Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis](https://scholariq.org/papers/efficacy-and-safety-of-adalimumab-in-japanese-patients-with-moderately-to/)
- [Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study](https://scholariq.org/papers/long-term-effectiveness-of-dupilumab-in-patients-with-atopic-dermatitis-results/)

## Researcher topics

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)

## Researcher university

- [Regeneron (United States)](https://scholariq.org/institutions/regeneron-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.